Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Martin Cannon

Concepts (299)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Dendritic Cells
26
2023
135
3.710
Why?
Ovarian Neoplasms
23
2023
450
3.700
Why?
Cancer Vaccines
13
2020
80
2.980
Why?
Immunotherapy
12
2019
235
1.920
Why?
Th17 Cells
3
2020
25
1.490
Why?
Antigens, Neoplasm
11
2019
148
1.320
Why?
CD4-Positive T-Lymphocytes
8
2023
158
1.060
Why?
Uterine Cervical Neoplasms
13
2011
276
0.950
Why?
Oncogene Proteins, Viral
7
2011
52
0.810
Why?
Neoplasm Recurrence, Local
3
2020
629
0.760
Why?
T-Lymphocytes, Regulatory
6
2011
82
0.730
Why?
T-Lymphocytes, Cytotoxic
12
2013
63
0.700
Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
3
2014
16
0.650
Why?
Lymphocytes, Tumor-Infiltrating
4
2019
76
0.610
Why?
Neoplasms
4
2019
1251
0.560
Why?
CD8-Positive T-Lymphocytes
11
2023
125
0.560
Why?
Antibodies, Monoclonal
5
2019
462
0.550
Why?
DNA-Binding Proteins
5
2007
418
0.540
Why?
Interleukin-17
2
2020
37
0.530
Why?
p38 Mitogen-Activated Protein Kinases
2
2014
93
0.510
Why?
Ascites
1
2014
28
0.450
Why?
T-Lymphocytes
5
2017
325
0.450
Why?
Immunologic Surveillance
2
2011
11
0.440
Why?
Female
42
2023
27081
0.400
Why?
Cytokines
4
2014
606
0.400
Why?
Signal Transduction
3
2017
1624
0.400
Why?
Carcinoma
2
2017
137
0.390
Why?
T-Lymphocytes, Helper-Inducer
2
2011
39
0.380
Why?
Immunotherapy, Active
1
2011
4
0.380
Why?
Serine Endopeptidases
3
2009
51
0.370
Why?
Cytotoxicity, Immunologic
7
2011
55
0.370
Why?
Humans
53
2023
50503
0.360
Why?
Adoptive Transfer
1
2009
30
0.330
Why?
Immunotherapy, Adoptive
3
2005
163
0.310
Why?
Interferon-gamma
7
2020
177
0.300
Why?
Epitopes, T-Lymphocyte
3
2008
25
0.290
Why?
Lymphocyte Activation
3
2005
164
0.280
Why?
Adjuvants, Immunologic
3
2011
51
0.270
Why?
Papillomavirus Vaccines
1
2007
67
0.270
Why?
Herpesvirus 4, Human
2
2005
37
0.270
Why?
Immunodominant Epitopes
2
2008
8
0.270
Why?
Cell Line, Tumor
13
2022
1398
0.260
Why?
Animals
16
2023
13124
0.250
Why?
Dependovirus
3
2011
102
0.230
Why?
HLA-A2 Antigen
3
2009
11
0.220
Why?
Cell Transformation, Viral
1
2003
25
0.210
Why?
Cell Line, Transformed
1
2003
73
0.210
Why?
Poxviridae Infections
1
2022
4
0.210
Why?
Poxviridae
1
2022
7
0.200
Why?
Oncolytic Virotherapy
1
2022
18
0.200
Why?
Myxoma virus
1
2022
14
0.200
Why?
Interferon Type I
1
2022
24
0.200
Why?
Cystadenocarcinoma, Serous
5
2009
71
0.200
Why?
Vaccination
4
2010
280
0.200
Why?
Disease-Free Survival
2
2020
444
0.190
Why?
Receptor, erbB-2
4
2008
75
0.190
Why?
Papillomavirus E7 Proteins
5
2011
31
0.190
Why?
Interleukin-10
2
2017
84
0.190
Why?
Genes, MHC Class I
3
2008
10
0.190
Why?
Testis
2
2011
66
0.180
Why?
Membrane Proteins
4
2011
332
0.180
Why?
Injections, Intradermal
1
2020
13
0.180
Why?
Immunity, Humoral
1
2020
22
0.180
Why?
Macrophages
4
2022
364
0.180
Why?
Coculture Techniques
3
2014
142
0.180
Why?
Flow Cytometry
8
2013
474
0.170
Why?
Folate Receptor 1
1
2020
25
0.170
Why?
Cell Movement
2
2019
247
0.170
Why?
Enzyme-Linked Immunosorbent Assay
2
2013
234
0.170
Why?
Carcinoma, Hepatocellular
1
2022
195
0.170
Why?
Mice
9
2023
5687
0.170
Why?
Carcinoma, Lewis Lung
1
2019
9
0.170
Why?
B-Lymphocytes
5
2017
171
0.170
Why?
Repressor Proteins
3
2011
148
0.160
Why?
Melanoma, Experimental
1
2019
40
0.160
Why?
Self Tolerance
1
2019
1
0.160
Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2019
1
0.160
Why?
Liver Neoplasms
1
2022
326
0.160
Why?
Transplantation, Autologous
1
2020
481
0.150
Why?
Aged
12
2020
9741
0.150
Why?
Cells, Cultured
6
2014
1571
0.150
Why?
Cytotoxicity Tests, Immunologic
4
2005
27
0.150
Why?
N-Acetylglucosaminyltransferases
1
2017
14
0.140
Why?
Programmed Cell Death 1 Receptor
1
2017
39
0.140
Why?
Middle Aged
16
2020
12611
0.140
Why?
HLA Antigens
4
2006
52
0.140
Why?
Receptors, Notch
1
2017
27
0.140
Why?
Human Umbilical Vein Endothelial Cells
2
2014
90
0.140
Why?
Neoplastic Stem Cells
1
2017
98
0.130
Why?
Carcinoma, Papillary
3
2005
47
0.130
Why?
Poliovirus Vaccine, Oral
2
2005
4
0.120
Why?
Genetic Vectors
3
2011
128
0.120
Why?
Poliovirus
2
2005
8
0.120
Why?
Adult
15
2011
13577
0.120
Why?
Neoplasm Proteins
1
2017
320
0.120
Why?
Clinical Trials, Phase I as Topic
1
2015
25
0.120
Why?
Adenocarcinoma
3
2004
397
0.120
Why?
Antigen Presentation
5
2009
25
0.120
Why?
Galectin 3
1
2014
14
0.120
Why?
Kallikreins
2
2005
18
0.120
Why?
Neoplasm Invasiveness
3
2017
269
0.110
Why?
Cystadenocarcinoma, Papillary
2
2005
14
0.110
Why?
Histocompatibility Antigens Class I
2
2005
46
0.110
Why?
Peptide Fragments
4
2009
209
0.110
Why?
Endometrial Neoplasms
2
2005
137
0.110
Why?
Uterine Neoplasms
2
2005
60
0.110
Why?
Papillomavirus Infections
3
2011
168
0.110
Why?
Mutation
1
2019
1280
0.100
Why?
Mice, Inbred C57BL
3
2017
1808
0.100
Why?
Intracellular Signaling Peptides and Proteins
2
2022
135
0.100
Why?
Lymphocytes
1
2013
149
0.100
Why?
Antigens, Viral
3
2007
42
0.100
Why?
Killer Cells, Natural
4
2005
106
0.100
Why?
V-Set Domain-Containing T-Cell Activation Inhibitor 1
1
2011
4
0.090
Why?
rho GTP-Binding Proteins
1
2011
6
0.090
Why?
Clonal Anergy
1
2011
13
0.090
Why?
A Kinase Anchor Proteins
1
2011
2
0.090
Why?
Drug Resistance, Neoplasm
5
2017
316
0.090
Why?
Calmodulin-Binding Proteins
1
2011
10
0.090
Why?
Antigen-Presenting Cells
1
2011
23
0.090
Why?
Antigens, Surface
1
2011
44
0.090
Why?
Human papillomavirus 16
1
2011
44
0.090
Why?
Antineoplastic Agents, Alkylating
1
2011
73
0.090
Why?
Uterine Cervical Dysplasia
1
2011
49
0.090
Why?
Immunity, Cellular
2
2008
63
0.090
Why?
Cyclophosphamide
1
2011
168
0.090
Why?
Prostate
1
2011
114
0.090
Why?
Diphosphonates
1
2011
90
0.090
Why?
Imidazoles
1
2011
127
0.090
Why?
Phenotype
1
2013
739
0.080
Why?
Gene Expression Regulation, Neoplastic
4
2011
833
0.080
Why?
Gene Expression Profiling
2
2005
1025
0.080
Why?
Papillomaviridae
3
2005
103
0.080
Why?
Neoplasm Staging
3
2007
746
0.080
Why?
Carrier Proteins
1
2011
298
0.080
Why?
K562 Cells
2
2008
40
0.080
Why?
Tumor Microenvironment
2
2023
222
0.080
Why?
CA-125 Antigen
1
2008
16
0.080
Why?
Immediate-Early Proteins
1
2008
19
0.080
Why?
Cytomegalovirus
1
2008
28
0.080
Why?
RNA, Messenger
4
2005
1089
0.080
Why?
Green Fluorescent Proteins
1
2008
90
0.080
Why?
Interleukin-4
2
2005
42
0.070
Why?
Antibody Formation
1
2007
50
0.070
Why?
Antibodies, Viral
1
2007
94
0.070
Why?
Prostatic Neoplasms
1
2011
384
0.070
Why?
Amino Acid Sequence
2
2005
574
0.070
Why?
RNA Interference
2
2017
178
0.070
Why?
Ovary
3
2017
103
0.070
Why?
Molecular Sequence Data
2
2005
778
0.070
Why?
Oligonucleotide Array Sequence Analysis
2
2005
405
0.070
Why?
Recombinant Proteins
1
2007
476
0.070
Why?
Hypersensitivity, Delayed
1
2005
19
0.060
Why?
Breast Neoplasms
3
2003
1201
0.060
Why?
Neoplasms, Squamous Cell
1
2005
7
0.060
Why?
Monocytes
2
2022
127
0.060
Why?
Cell Line
4
2010
988
0.060
Why?
Electroporation
1
2005
17
0.060
Why?
Poliomyelitis
1
2005
5
0.060
Why?
Enterotoxins
1
2005
12
0.060
Why?
Gene Transfer Techniques
1
2005
41
0.060
Why?
Interleukin-12
1
2005
29
0.060
Why?
Genes, erbB-2
1
2005
8
0.060
Why?
Reverse Transcriptase Polymerase Chain Reaction
4
2008
572
0.060
Why?
Immunologic Memory
1
2005
29
0.060
Why?
Antigens, Heterophile
1
2005
1
0.060
Why?
Burkitt Lymphoma
1
2005
14
0.060
Why?
Plasmodium falciparum
1
2005
19
0.060
Why?
Malaria, Falciparum
1
2005
14
0.060
Why?
Endemic Diseases
1
2005
22
0.060
Why?
Epstein-Barr Virus Infections
1
2005
30
0.060
Why?
Gangliosides
1
2004
5
0.060
Why?
Ascitic Fluid
1
2004
12
0.060
Why?
Proteins
2
2005
339
0.060
Why?
Genetic Therapy
1
2005
120
0.060
Why?
Ovariectomy
1
2004
115
0.060
Why?
Vaccines, Subunit
1
2004
15
0.060
Why?
Hysterectomy
1
2004
88
0.060
Why?
Immunization, Passive
1
2004
30
0.060
Why?
Interleukin-6
1
2005
261
0.060
Why?
Clinical Trials as Topic
2
2007
486
0.060
Why?
Tumor Necrosis Factor-alpha
2
2019
393
0.050
Why?
Cell Differentiation
2
2004
640
0.050
Why?
Protein Binding
1
2005
654
0.050
Why?
Epithelial Cells
1
2005
207
0.050
Why?
Vesiculovirus
1
2022
6
0.050
Why?
Virus Latency
1
2003
52
0.050
Why?
Vaccinia virus
1
2022
6
0.050
Why?
Host Specificity
1
2022
5
0.050
Why?
Cell Adhesion Molecules
1
2003
86
0.050
Why?
Cell Communication
1
2003
68
0.050
Why?
Mammals
1
2022
50
0.050
Why?
Nucleotidyltransferases
1
2022
14
0.050
Why?
Disease Models, Animal
2
2022
1436
0.050
Why?
Tumor Cells, Cultured
4
2003
457
0.050
Why?
Xenograft Model Antitumor Assays
2
2017
212
0.050
Why?
Disease Progression
2
2019
829
0.050
Why?
Radiotherapy
1
2002
125
0.050
Why?
Rabbits
1
2022
372
0.050
Why?
Down-Regulation
1
2003
340
0.050
Why?
Blood Transfusion
1
2002
129
0.050
Why?
Viral Proteins
1
2022
153
0.050
Why?
Immunohistochemistry
4
2005
957
0.040
Why?
Carcinoma, Squamous Cell
1
2004
326
0.040
Why?
Transcriptome
1
2022
313
0.040
Why?
Endothelium
1
2019
37
0.040
Why?
Intercellular Adhesion Molecule-1
1
2019
62
0.040
Why?
Gene Expression
3
2008
610
0.040
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2004
1000
0.040
Why?
Injections, Intraperitoneal
2
2010
59
0.040
Why?
Tissue Banks
1
2017
9
0.040
Why?
STAT3 Transcription Factor
1
2017
77
0.040
Why?
Antibodies, Monoclonal, Humanized
3
2004
226
0.040
Why?
Mice, Inbred NOD
1
2017
91
0.040
Why?
Glycosylation
1
2017
102
0.040
Why?
Tumor Burden
1
2017
130
0.030
Why?
RNA, Small Interfering
1
2017
208
0.030
Why?
Multiple Myeloma
1
2011
2998
0.030
Why?
Protein Processing, Post-Translational
1
2017
156
0.030
Why?
Lung Neoplasms
1
2002
601
0.030
Why?
Kaplan-Meier Estimate
1
2017
464
0.030
Why?
Survival Analysis
2
2010
661
0.030
Why?
Apoptosis
2
2014
1097
0.030
Why?
Pore Forming Cytotoxic Proteins
2
2005
9
0.030
Why?
Perforin
2
2005
11
0.030
Why?
Anti-Bacterial Agents
1
2019
745
0.030
Why?
Neovascularization, Pathologic
1
2014
155
0.030
Why?
Interleukin-2
2
2003
71
0.030
Why?
Membrane Glycoproteins
2
2005
245
0.030
Why?
Vaginal Smears
1
2011
28
0.020
Why?
Organ Specificity
1
2011
109
0.020
Why?
Prostate-Specific Antigen
1
2011
44
0.020
Why?
DNA, Viral
1
2011
136
0.020
Why?
Time Factors
2
2010
2935
0.020
Why?
Major Histocompatibility Complex
1
2010
12
0.020
Why?
Prognosis
2
2005
1978
0.020
Why?
Transduction, Genetic
1
2008
46
0.020
Why?
Fluorescent Antibody Technique
1
2008
104
0.020
Why?
Leukocytes, Mononuclear
1
2008
118
0.020
Why?
Alphapapillomavirus
1
2007
13
0.020
Why?
T-Lymphocyte Subsets
1
2007
39
0.020
Why?
Models, Immunological
1
2007
7
0.020
Why?
Aged, 80 and over
2
2005
3226
0.020
Why?
Immune Tolerance
1
2007
84
0.020
Why?
Adolescent
2
2011
6443
0.020
Why?
HLA-B Antigens
1
2006
7
0.020
Why?
Clone Cells
1
2006
70
0.020
Why?
Immunity, Innate
1
2007
105
0.020
Why?
Male
3
2011
25907
0.020
Why?
Claudin-3
1
2005
5
0.020
Why?
Claudin-4
1
2005
7
0.020
Why?
Combined Modality Therapy
1
2007
641
0.020
Why?
Mice, Inbred C3H
1
2005
85
0.020
Why?
Peptides
1
2006
221
0.020
Why?
Protein Sorting Signals
1
2005
9
0.020
Why?
Protein Engineering
1
2005
18
0.010
Why?
Histocompatibility Antigens Class II
1
2005
37
0.010
Why?
Species Specificity
1
2005
187
0.010
Why?
Plasmids
1
2005
164
0.010
Why?
Mice, SCID
1
2005
178
0.010
Why?
Protein Folding
1
2005
48
0.010
Why?
Epithelium
1
2004
66
0.010
Why?
Endocytosis
1
2005
55
0.010
Why?
Carboplatin
1
2004
54
0.010
Why?
Receptors, Cell Surface
1
2005
116
0.010
Why?
Radiotherapy, Adjuvant
1
2004
64
0.010
Why?
Paclitaxel
1
2004
84
0.010
Why?
Transfection
1
2005
356
0.010
Why?
Antineoplastic Agents, Hormonal
1
2004
49
0.010
Why?
Polymerase Chain Reaction
1
2005
449
0.010
Why?
Antibody-Dependent Cell Cytotoxicity
1
2003
12
0.010
Why?
Tumor Stem Cell Assay
1
2003
17
0.010
Why?
Proportional Hazards Models
1
2005
415
0.010
Why?
Cervix Uteri
1
2004
42
0.010
Why?
Keratinocytes
1
2004
77
0.010
Why?
Up-Regulation
1
2005
446
0.010
Why?
Swine
1
2005
408
0.010
Why?
Kinetics
1
2005
623
0.010
Why?
Receptors, Interleukin-2
1
2002
6
0.010
Why?
Lymphocyte Subsets
1
2002
14
0.010
Why?
Receptors, Antigen, T-Cell
1
2003
48
0.010
Why?
Cell Culture Techniques
1
2003
96
0.010
Why?
Antigens, CD19
1
2002
29
0.010
Why?
Receptors, IgG
1
2002
22
0.010
Why?
Leukocytes
1
2003
69
0.010
Why?
Cell Death
1
2003
175
0.010
Why?
Doxorubicin
1
2004
236
0.010
Why?
Immunophenotyping
1
2002
105
0.010
Why?
Cisplatin
1
2004
286
0.010
Why?
Survival Rate
1
2005
909
0.010
Why?
Tumor Virus Infections
1
2002
47
0.010
Why?
Antibodies, Monoclonal, Murine-Derived
1
2002
45
0.010
Why?
Young Adult
1
2011
4102
0.010
Why?
Fatal Outcome
1
2002
197
0.010
Why?
Cell Division
1
2002
291
0.010
Why?
Case-Control Studies
1
2004
1156
0.010
Why?
Prospective Studies
1
2004
2378
0.010
Why?
Risk Factors
1
2004
3724
0.010
Why?
Antineoplastic Agents
1
2002
1172
0.010
Why?
Cannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description